CGS 125

Drug Profile

CGS 125

Alternative Names: CGS-125; trans-capsaicin - CapGenesis Therapeutics

Latest Information Update: 19 Jan 2016

Price : $50

At a glance

  • Originator CapGenesis Therapeutics
  • Class Antipruritics; Catechols; Local anaesthetics; Monounsaturated fatty acids; Non-opioid analgesics; Polyunsaturated alkamides; Small molecules
  • Mechanism of Action TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Osteoarthritis

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 23 Nov 2015 Clinical trials in Osteoarthritis in Dominican Republic (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top